Daniel F. Gaddy

984 total citations
20 papers, 798 citations indexed

About

Daniel F. Gaddy is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Biomaterials. According to data from OpenAlex, Daniel F. Gaddy has authored 20 papers receiving a total of 798 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Radiology, Nuclear Medicine and Imaging, 8 papers in Oncology and 7 papers in Biomaterials. Recurrent topics in Daniel F. Gaddy's work include Radiopharmaceutical Chemistry and Applications (7 papers), Nanoparticle-Based Drug Delivery (7 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Daniel F. Gaddy is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (7 papers), Nanoparticle-Based Drug Delivery (7 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Daniel F. Gaddy collaborates with scholars based in United States and Canada. Daniel F. Gaddy's co-authors include Douglas S. Lyles, Bart S. Hendriks, Thomas J. Wickham, Helen Lee, Shannon C. Leonard, Dmitri B. Kirpotin, Elena Geretti, Victor Moyo, Kathy D. Miller and Karen Campbell and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Diabetes.

In The Last Decade

Daniel F. Gaddy

19 papers receiving 783 citations

Peers

Daniel F. Gaddy
Gillie A. Roth United States
Hassan Dianat‐Moghadam Iran
Emily C. Gale United States
Timothy M. Jacobs United States
Makan Khoshnejad United States
Kelsey L. Swingle United States
Derfogail Delcassian United States
Niels Dammes Israel
Fangfang Chen China
Ans De Beuckelaer Belgium
Gillie A. Roth United States
Daniel F. Gaddy
Citations per year, relative to Daniel F. Gaddy Daniel F. Gaddy (= 1×) peers Gillie A. Roth

Countries citing papers authored by Daniel F. Gaddy

Since Specialization
Citations

This map shows the geographic impact of Daniel F. Gaddy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel F. Gaddy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel F. Gaddy more than expected).

Fields of papers citing papers by Daniel F. Gaddy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel F. Gaddy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel F. Gaddy. The network helps show where Daniel F. Gaddy may publish in the future.

Co-authorship network of co-authors of Daniel F. Gaddy

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel F. Gaddy. A scholar is included among the top collaborators of Daniel F. Gaddy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel F. Gaddy. Daniel F. Gaddy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lee, Helen, Daniel F. Gaddy, Manuela Ventura, et al.. (2018). Companion Diagnostic 64Cu-Liposome Positron Emission Tomography Enables Characterization of Drug Delivery to Tumors and Predicts Response to Cancer Nanomedicines. Theranostics. 8(9). 2300–2312. 50 indexed citations
2.
Klinz, Stephan G., Shannon C. Leonard, Nancy Paz, et al.. (2018). DNA damage with liposomal irinotecan (nal-IRI) in pancreatic cancer xenografts: Multimodal analysis of deposition characteristics.. Journal of Clinical Oncology. 36(15_suppl). e16205–e16205. 2 indexed citations
3.
Leonard, Shannon C., Nancy Paz, Stephan G. Klinz, et al.. (2018). Deposition characteristics and resulting DNA damage patterns of liposomal irinotecan (nal-IRI) in pancreatic cancer xenografts.. Journal of Clinical Oncology. 36(4_suppl). 335–335. 4 indexed citations
4.
Leonard, Shannon C., Helen Lee, Daniel F. Gaddy, et al.. (2017). Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer. Anti-Cancer Drugs. 28(10). 1086–1096. 25 indexed citations
5.
Lee, Helen, Anthony F. Shields, Barry A. Siegel, et al.. (2017). 64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer. Clinical Cancer Research. 23(15). 4190–4202. 285 indexed citations
6.
Leonard, Shannon C., Daniel F. Gaddy, Helen Lee, et al.. (2017). Abstract 5151: Nanoliposomal irinotecan (nal-IRI, MM-398) has greater anti-tumor activity than topotecan and irinotecan in mouse models of small cell lung cancer. Cancer Research. 77(13_Supplement). 5151–5151.
7.
Gaddy, Daniel F., Helen Lee, Nancy Paz, et al.. (2016). Abstract 4830: Preclinical anti-tumor activity of nanoliposomal irinotecan (Nal-IRI, MM-398) + 5-FU + oxaliplatin in pancreatic cancer. Cancer Research. 76(14_Supplement). 4830–4830. 1 indexed citations
8.
Gaddy, Daniel F., Helen Lee, Jinzi Zheng, et al.. (2015). Whole-body organ-level and kidney micro-dosimetric evaluations of 64Cu-loaded HER2/ErbB2-targeted liposomal doxorubicin (64Cu-MM-302) in rodents and primates. EJNMMI Research. 5(1). 24–24. 15 indexed citations
9.
Geretti, Elena, Shannon C. Leonard, Nancy Dumont, et al.. (2015). Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302). Molecular Cancer Therapeutics. 14(9). 2060–2071. 51 indexed citations
10.
Tilstra, Jeremy S., Daniel F. Gaddy, Jing Zhao, et al.. (2014). Pharmacologic IKK/NF-κB inhibition causes antigen presenting cells to undergo TNFα dependent ROS-mediated programmed cell death. Scientific Reports. 4(1). 3631–3631. 25 indexed citations
11.
Lee, Helen, Jinzi Zheng, Daniel F. Gaddy, et al.. (2014). A gradient-loadable 64Cu-chelator for quantifying tumor deposition kinetics of nanoliposomal therapeutics by positron emission tomography. Nanomedicine Nanotechnology Biology and Medicine. 11(1). 155–165. 46 indexed citations
12.
Hendriks, Bart S., Stephan G. Klinz, Joseph G. Reynolds, et al.. (2013). Impact of Tumor HER2/ERBB2 Expression Level on HER2-Targeted Liposomal Doxorubicin-Mediated Drug Delivery: Multiple Low-Affinity Interactions Lead to a Threshold Effect. Molecular Cancer Therapeutics. 12(9). 1816–1828. 50 indexed citations
13.
Geretti, Elena, Shannon C. Leonard, Daniel F. Gaddy, et al.. (2013). Abstract 3271: Tumor priming with cyclophosphamide increases delivery and activity of Her2-targeted liposomal doxorubicin (MM-302) in preclinical models of breast cancer.. Cancer Research. 73(8_Supplement). 3271–3271. 1 indexed citations
14.
Klinz, Stephan G., Daniel F. Gaddy, Elena Geretti, et al.. (2011). Abstract 3637: MM-302, a HER2-targeted liposomal doxorubicin, shows binding/uptake and efficacy in HER2 2+ cells and xenograft models. Cancer Research. 71(8_Supplement). 3637–3637. 2 indexed citations
15.
Geretti, Elena, Bart S. Hendriks, Daniel F. Gaddy, et al.. (2011). Abstract C90: HER2-targeted liposomal doxorubicin MM-302 has a favorable cardiosafety profile in preclinical models.. Molecular Cancer Therapeutics. 10(11_Supplement). C90–C90. 3 indexed citations
16.
Rajawat, Yogendra Singh, Zoe Hilioti, Xue Jia, et al.. (2010). Generation of a tumor vaccine candidate based on conjugation of a MUC1 peptide to polyionic papillomavirus virus-like particles. Cancer Immunology Immunotherapy. 59(11). 1685–1696. 52 indexed citations
17.
18.
Gaddy, Daniel F. & Paul D. Robbins. (2008). Current status of gene therapy for rheumatoid arthritis. Current Rheumatology Reports. 10(5). 398–404. 3 indexed citations
19.
Gaddy, Daniel F. & Douglas S. Lyles. (2006). Oncolytic Vesicular Stomatitis Virus Induces Apoptosis via Signaling through PKR, Fas, and Daxx. Journal of Virology. 81(6). 2792–2804. 58 indexed citations
20.
Gaddy, Daniel F. & Douglas S. Lyles. (2005). Vesicular Stomatitis Viruses Expressing Wild-Type or Mutant M Proteins Activate Apoptosis through Distinct Pathways. Journal of Virology. 79(7). 4170–4179. 97 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gillie A. Roth Breakdown of academic impact, for papers by Hassan Dianat‐Moghadam Breakdown of academic impact, for papers by Emily C. Gale Breakdown of academic impact, for papers by Timothy M. Jacobs Breakdown of academic impact, for papers by Makan Khoshnejad Breakdown of academic impact, for papers by Kelsey L. Swingle Breakdown of academic impact, for papers by Derfogail Delcassian Breakdown of academic impact, for papers by Niels Dammes Breakdown of academic impact, for papers by Fangfang Chen Breakdown of academic impact, for papers by Ans De Beuckelaer
Rankless by CCL
2026